Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort-Reference-Cited by-同舟云学术

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

Published:2024-01-25 Issue:1 Volume:42 Page:127-135
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Emiloju Oluwadunni E.,Yin Jun,Koubek Emily,Reid Joel M.,Borad Mitesh J.,Lou Yanyan,Seetharam Mahesh,Edelman Martin J.,Sausville Edward A.,Jiang Yixing,Kaseb Ahmed O.,Posey James A.,Davis Sarah L.,Gores Gregory J.,Roberts Lewis R.,Takebe Naoko,Schwartz Gary K.,Hendrickson Andrea E. Wahner,Kaufmann Scott H.,Adjei Alex A.,Hubbard Joleen M.,Costello Brian A.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10637-024-01420-8.pdf

Reference37 articles.

1. Kale J et al (2018) Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep 19(9)

2. Tse C et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421–3428

3. Harrison CN et al (2022) Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol 40(15):1671–1680

4. Pullarkat VA et al (2021) Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov 11(6):1440–1453

5. Rudin CM et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163–3169

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Bcl‐2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma;International Journal of Cell Biology;2024-01